Using CT imaging to guide treatment for liver cancer after surgery
CT Imaging for Guiding Postoperative Adjuvant Transarterial Chemoembolization for Hepatocellular Carcinoma
This study is testing if CT scans can help doctors choose the best patients for a specific treatment after liver cancer surgery to improve their chances of living longer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1488 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Zhujiang Hospital Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06156748 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of CT imaging in predicting the benefits of postoperative adjuvant transarterial chemoembolization (PA-TACE) for patients who have undergone surgical resection for hepatocellular carcinoma (HCC). The study aims to identify reliable biomarkers that can help select candidates who are most likely to benefit from PA-TACE, which may improve survival outcomes. By analyzing CT scans taken shortly before surgery, researchers hope to enhance treatment decision-making for this patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are patients who have undergone curative surgical resection for hepatocellular carcinoma and have had CT scans within one month prior to surgery.
Not a fit: Patients with prior antitumor treatment, macrovascular thrombosis, metastasis, or other specified exclusion criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved survival rates for patients with resected hepatocellular carcinoma by optimizing treatment selection.
How similar studies have performed: While the approach of using imaging to guide treatment decisions is common, the specific application of CT imaging for PA-TACE in HCC is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * CT scans acquired no more than one month before surgery * Confirmation of HCC diagnosis by pathological examination * Curative surgical resection Exclusion Criteria: * Prior antitumor treatment * Macrovascular thrombosis or metastasis * Perioperative mortality * Unqualified image artifacts * Tumor rupture * MVI status not reported
Where this trial is running
Guangzhou, Guangdong
- ZhuJiang Hospital of Southern Medical University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Li, MD
- Email: lixinmingsmu@163.com
- Phone: 86-020-62783269
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.